Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …

Epigenetic events, such as aberrant DNA methylation, have been demonstrated to silence
the expression of many genes that suppress malignancy. Since the event is reversible, it is …

Abstract Decitabine (5-aza-2′-deoxycytidine) inhibits DNA methylation and has dual effects
on neoplastic cells, including the reactivation of silenced genes and differentiation at low …

The preclinical pharmacology of 5-aza-2′-deoxycytidine (decitabine, 5AZA-CdR) is
reviewed. 5AZA-CdR, an analogue of deoxycytidine, is a prodrug that requires metabolic …

Abstract Decitabine (5‐aza‐2′‐deoxycytidine) is a hypomethylating agent with a dual
mechanism of action: reactivation of silenced genes and differentiation at low doses, and …

Aza-2′-deoxycytidine (5-Aza-CdR; Decitabine) is an active antineoplastic agent in patients
with leukemia. Since 5-Aza-CdR is an S phase specific agent and has a short plasma half …

Purpose The nucleoside analog 5-aza-2′-deoxycytidine (5-aza-CdR, decitabine) is a
potent inhibitor of DNA methylation in vitro. Cellular treatment with this agent induces the re …

Background The inactivation of tumor suppressor genes (TSGs) by aberrant DNA
methylation plays an important role in the development of malignancy. Since this epigenetic …

The major goal of epigenetic therapy is to reverse aberrant promoter hypermethylation and
restore normal function of tumor suppressor genes by the use of chromatin-modifying drugs …

Abstract The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza®) and its deoxy
derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen®), are the most widely used …